Abstract
Background: Few studies in the literature have analyzed the long-term neurodevelopmental outcomes of the administration of a multicomponent versus a soybean-based lipid emulsion (LE) in preterm infants receiving parenteral nutrition (PN). A recent randomized controlled trial conducted in our unit provided evidence of better growth in head circumference during the hospital stay in those who received a multicomponent LE. Methods: This is a 24 month follow-up study of preterm infants, previously enrolled in a randomized trial, who received a multicomponent LE (SMOFlipid((R))) or a standard soybean-based one (Intralipid((R))). We evaluated neurodevelopmental outcomes at 24 months of corrected age (CA) in the two groups. Results: Ninety-three children were followed up to the age of 24 months CA. Due to the peculiar time frame of the SARS-CoV-2 pandemic, neurodevelopmental outcomes were evaluated only in 77 children: 37 in the SMOFlipid((R)) group and 40 in the Intralipid((R)) group. No differences in major disability rates or in Griffith's evaluation were found between the two groups. Conclusions: In our population study, the administration of a multicomponent LE containing fish oil, compared to a soybean-based LE, had no significant effects on neurodevelopmental outcomes in preterm infants at 24 months CA.
Lingua originale | English |
---|---|
pagine (da-a) | N/A-N/A |
Rivista | Nutrients |
Volume | 15 |
DOI | |
Stato di pubblicazione | Pubblicato - 2022 |
Keywords
- Griffith’s Mental Development Scales
- Intralipid
- SMOFlipid
- multicomponent lipid emulsion
- neonatal outcome
- parenteral nutrition
- preterm infants
- very-low-birth-weight infants